| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TVTX | Common Stock | Award | $0 | +4,500 | +14% | $0.000000 | 37,138 | 13 Aug 2021 | Direct | F1, F2 |
| transaction | TVTX | Common Stock | Sale | $24,085 | -1,407 | -3.8% | $17.12 | 35,731 | 17 Aug 2021 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 9,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On August 13, 2021, a portion of the PRSUs vested upon the Issuer's confirmation of the satisfaction of a performance criterion related to the interim data read-out from the PROTECT study. |
| F2 | Includes 931 shares of the Issuer's common stock acquired by the reporting person on May 31, 2021 pursuant to an employee stock purchase program. |
| F3 | Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. |